A. Lage

592 total citations
31 papers, 495 citations indexed

About

A. Lage is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, A. Lage has authored 31 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Immunology and 9 papers in Molecular Biology. Recurrent topics in A. Lage's work include Immunotherapy and Immune Responses (8 papers), Estrogen and related hormone effects (7 papers) and Glycosylation and Glycoproteins Research (6 papers). A. Lage is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Estrogen and related hormone effects (7 papers) and Glycosylation and Glycoproteins Research (6 papers). A. Lage collaborates with scholars based in Cuba, United States and Belgium. A. Lage's co-authors include Gabriela Gonzalez, Tania Crombet, Rolando Pérez, Mauricio Catalá, Patricia Marinello, Juan C. Hernández, Gerardo Guillén, Lambert Skoog, Keith C. Hayes and Lynne M. Ausman and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

A. Lage

29 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Lage Cuba 10 264 195 168 109 76 31 495
NK Cheung United States 9 168 0.6× 229 1.2× 200 1.2× 95 0.9× 37 0.5× 13 597
Pia M. Challita-Eid United States 10 279 1.1× 255 1.3× 142 0.8× 80 0.7× 79 1.0× 18 556
Maria Liljefors Sweden 12 224 0.8× 243 1.2× 133 0.8× 85 0.8× 30 0.4× 20 451
Shashi Singh Pawar United States 10 112 0.4× 241 1.2× 309 1.8× 81 0.7× 70 0.9× 19 650
Ruby Alonso Cuba 14 209 0.8× 422 2.2× 152 0.9× 81 0.7× 35 0.5× 22 661
A J Infante United States 12 97 0.4× 312 1.6× 176 1.0× 224 2.1× 62 0.8× 21 629
Jennifer B. Jacob United States 13 159 0.6× 293 1.5× 194 1.2× 105 1.0× 33 0.4× 21 500
Jan Davidson‐Moncada United States 12 228 0.9× 215 1.1× 161 1.0× 45 0.4× 61 0.8× 49 518
Hyung Geun Song South Korea 15 133 0.5× 87 0.4× 165 1.0× 34 0.3× 79 1.0× 39 453
Aline Martayan Italy 13 122 0.5× 287 1.5× 148 0.9× 45 0.4× 37 0.5× 24 546

Countries citing papers authored by A. Lage

Since Specialization
Citations

This map shows the geographic impact of A. Lage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Lage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Lage more than expected).

Fields of papers citing papers by A. Lage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Lage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Lage. The network helps show where A. Lage may publish in the future.

Co-authorship network of co-authors of A. Lage

This figure shows the co-authorship network connecting the top 25 collaborators of A. Lage. A scholar is included among the top collaborators of A. Lage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Lage. A. Lage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dy, Grace K., Tania Crombet, Kalet León, et al.. (2019). EP1.04-23 Ongoing Phase II Trial of Anti-PD1 Therapy in Combination with CIMAvax-EGF in Patients with Advanced NSCLC or Squamous Cell Head and Neck Cancer. Journal of Thoracic Oncology. 14(10). S970–S970. 2 indexed citations
2.
Dy, Grace K., Marvin Reid, Kwanghyuk Lee, et al.. (2018). P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S740–S740. 2 indexed citations
3.
Sánchez, Lizet, et al.. (2014). Evaluating The Effect Of Immunotherapy In Advanced Non-Small- Cell Lung Cancer Patients Using Two Components Mixture Model. Value in Health. 17(7). A566–A566. 1 indexed citations
4.
Gonzalez, Gabriela, Tania Crombet, & A. Lage. (2010). Chronic Vaccination with a Therapeutic EGF-Based Cancer Vaccine: A Review of Patients Receiving Long Lasting Treatment. Current Cancer Drug Targets. 11(1). 103–110. 27 indexed citations
5.
Gonzalez, Gabriela & A. Lage. (2007). Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment. Current Cancer Drug Targets. 7(3). 229–241. 29 indexed citations
6.
Lage, A., et al.. (2005). Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology. Current Cancer Drug Targets. 5(8). 611–627. 17 indexed citations
7.
Neninger, Elia, Tania Crombet, Marta Osorio, et al.. (2005). Vaccination with EGF active immunotherapy improves survival in advanced non small cell lung cancer (NSCLC) patients: Interim analysis of a randomized phase II trial. Journal of Clinical Oncology. 23(16_suppl). 7210–7210. 3 indexed citations
8.
Crombet, Tania, et al.. (2004). 282 Use of the humanized anti-EGFR antibody h-R3 and radiotherapy for the treatment of patients with high-grade astrocytic tumors. European Journal of Cancer Supplements. 2(8). 86–87. 1 indexed citations
9.
Gonzalez, Gabriela, Carmen Viada, Elia Neninger, et al.. (2004). Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials. Journal of Clinical Oncology. 22(14_suppl). 2548–2548. 4 indexed citations
10.
Montero, Enrique, et al.. (2002). Autoimmunization to Epidermal Growth Factor, a component of the immunological homunculus. Autoimmunity Reviews. 1(1-2). 89–95. 23 indexed citations
11.
Montero, Enrique, Gil Reyes, Olga Torres, et al.. (2002). Immunodiagnosis and therapeutic immunosuppression in rheumatoid arthritis with ior t1 (anti-CD6) monoclonal antibody. Arthritis Research. 4(Suppl 1). 114–114. 7 indexed citations
12.
Crombet, Tania, Olga Torres, Vanina Rodríguez, et al.. (2001). Phase I Clinical Evaluation of a Neutralizing Monoclonal Antibody Against Epidermal Growth Factor Receptor in Advanced Brain Tumor Patients: Preliminary Study. Hybridoma. 20(2). 131–136. 49 indexed citations
13.
Montero, Enrique, et al.. (2000). Tumor-specific immunotherapy based on dominant models of natural tolerance. Medical Hypotheses. 54(4). 531–536. 7 indexed citations
14.
Arce, Sergio, et al.. (1999). Novel Cross-Reactive Anti-Idiotype Antibodies With Properties Close to the Human Intravenous Immunoglobulin (IVIg). Hybridoma. 18(3). 263–272. 10 indexed citations
15.
Gonzalez, Gabriela, Tania Crombet, Mauricio Catalá, et al.. (1998). A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial. Annals of Oncology. 9(4). 431–435. 127 indexed citations
16.
17.
Lombardero, J, Rosa Ana Pérez, & A. Lage. (1986). Epidermal growth factor inhibits thymidine incorporation in Ehrlich ascites tumor cells in vivo.. PubMed. 33(4). 423–9. 5 indexed citations
18.
Moreno, Dolores, et al.. (1985). Factors associated with prognosis in human breast cancer. V. The simultaneous use of estrogen and progesterone receptor measurements for prediction of short-term relapse.. PubMed. 32(2). 247–56. 4 indexed citations
19.
Lage, A., et al.. (1982). Experimental approach for the search of effective drug combination in cancer chemotherapy.. PubMed. 29(1). 65–71. 1 indexed citations
20.
Ausman, Lynne M., Keith C. Hayes, A. Lage, & D.M. Hegsted. (1970). Nursery care and growth of Old and New World infant monkeys.. PubMed. 20(5). 907–13. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by NK Cheung Breakdown of academic impact, for papers by Pia M. Challita-Eid Breakdown of academic impact, for papers by Maria Liljefors Breakdown of academic impact, for papers by Shashi Singh Pawar Breakdown of academic impact, for papers by Ruby Alonso Breakdown of academic impact, for papers by A J Infante Breakdown of academic impact, for papers by Jennifer B. Jacob Breakdown of academic impact, for papers by Jan Davidson‐Moncada Breakdown of academic impact, for papers by Hyung Geun Song Breakdown of academic impact, for papers by Aline Martayan
Rankless by CCL
2026